BioInsights - Adenovirus vector manufacturing platform using CIMmultus™️ QA assures the supply of safe vaccines

Adenovirus vector manufacturing platform using CIMmultus™️ QA assures the supply of safe vaccines

Cell & Gene Therapy Insights 2021; 7(8), 1125

10.18609/cgti.2021.147

Published: 4 October 2021
FastFacts
Hana Jug

Watch the video or read the poster to learn: 

  • Why downstream processing remains one of the main bottlenecks in adenoviral vector manufacturing 
  • How an adenoviral vector purification platform using CIMmultus QA as the key purification step, secures fast and robust process with better purity 
  • CIMmultus™QA offers high capacity and high yields of adenovirus, results in cost reduction and overcomes raw material supply bottlenecks 

Hana Jug is a Project Manager in process development for viral vectors and vaccines at BIA Separations, a Sartorius company. Hana has outstanding experience in downstream purification and analytics of demanding biologics. She has successfully managed several projects for clients in clinical phases, mainly in the field of gene therapy using adeno-associated virus, and vaccines using the adenovirus platform. She holds a BS in Biology from the University of Ljubljana, Slovenia.




We hope you enjoyed this FastFacts video. You can also view the summary here.



Authorship & Conflict of Interest

Contributions:  All  named  authors  take  responsibility  for  the  integrity  of  the  work  as a  whole,  and  have given their approval for this version to be published.

Acknowledgements: The author would like to thank Katja Vrabec, Ana Mavri and Maja Leskovec for their help with this FastFacts article.

Disclosure  and  potential  conflicts  of  interest: H Jug is an employee of BIA Separations, a Sartorius Company. The author has no other conflicts of interest to disclose. 

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

Article & copyright information

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which  allows  anyone  to  copy,  distribute,  and  transmit  the  article  provided  it  is  properly  attributed  in  the  manner specified below. No commercial use without permission.

Attribution: Copyright © 2021 BIA Separations, now a Sartorius company. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: From a FastFacts video recorded on: Sep 17 2021; Publication date: Oct 05 2021.